Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5.Currie, S.L., Lau, D.K.W., Doane, J.J., Whitby, F.G., Okon, M., McIntosh, L.P., Graves, B.J.
(2017) Nucleic Acids Res. 45: 2223-2241
- PubMed: 28161714
- DOI: 10.1093/nar/gkx068
- Primary Citation of Related Structures:
- PubMed Abstract:
Autoinhibition enables spatial and temporal regulation of cellular processes by coupling protein activity to surrounding conditions, often via protein partnerships or signaling pathways. We report the molecular basis of DNA-binding autoinhibition of ...
Autoinhibition enables spatial and temporal regulation of cellular processes by coupling protein activity to surrounding conditions, often via protein partnerships or signaling pathways. We report the molecular basis of DNA-binding autoinhibition of ETS transcription factors ETV1, ETV4 and ETV5, which are often overexpressed in prostate cancer. Inhibitory elements that cooperate to repress DNA binding were identified in regions N- and C-terminal of the ETS domain. Crystal structures of these three factors revealed an α-helix in the C-terminal inhibitory domain that packs against the ETS domain and perturbs the conformation of its DNA-recognition helix. Nuclear magnetic resonance spectroscopy demonstrated that the N-terminal inhibitory domain (NID) is intrinsically disordered, yet utilizes transient intramolecular interactions with the DNA-recognition helix of the ETS domain to mediate autoinhibition. Acetylation of selected lysines within the NID activates DNA binding. This investigation revealed a distinctive mechanism for DNA-binding autoinhibition in the ETV1/4/5 subfamily involving a network of intramolecular interactions not present in other ETS factors. These distinguishing inhibitory elements provide a platform through which cellular triggers, such as protein-protein interactions or post-translational modifications, may specifically regulate the function of these oncogenic proteins.
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112-5650, USA.,Howard Hughes Medical Institute, Chevy Chase, MD 20815-6789, USA.,Department of Biochemistry and Molecular Biology, Department of Chemistry, and Michael Smith Laboratories, University of British Columbia, Vancouver BC, V6T 1Z3, Canada.,Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112-5550, USA.,Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112-5550, USA.